Cessation – Smoke Master

For Smokers Who Struggle to Quit, Reiterate Experts, Vapes Are a Viable Smoking Cessation Option

admin — Mon, 17 Aug 2026 12:20:56 +0000

A growing body of scientific evidence is prompting healthcare professionals to reconsider how they discuss smoking cessation with adult patients. A new Special Communication published in JAMA by an expert panel convened by the Society for Research on Nicotine and Tobacco (SRNT) argues that nicotine-containing e-cigarettes should be included in conversations about quitting smoking alongside established cessation therapies, particularly for smokers who have struggled to quit using conventional methods.

The guidance reflects a broader shift towards tobacco harm reduction, recognising that while nicotine products may not be entirely risk-free, the overwhelming burden of disease comes from inhaling the toxic chemicals created by burning tobacco rather than from nicotine itself. In the United States alone, cigarette smoking is responsible for more than 480,000 deaths each year, while globally tobacco use claims more than eight million lives annually, according to World Health Organization data.

Although smoking prevalence has declined substantially over the past few decades, progress has slowed among some population groups. Middle-aged and older smokers, many of whom have smoked for decades, often experience greater difficulty quitting because of long-term nicotine dependence and deeply ingrained behavioural habits. For these smokers, finding an effective cessation strategy can be the difference between continuing to inhale thousands of combustion-related toxicants every day or moving to a substantially lower-risk alternative.

Clinicians need practical guidance

Rather than promoting a single approach, the expert panel recommends patient-centred discussions that take into account individual preferences, previous quit attempts and treatment goals.

The new recommendations were developed after clinicians increasingly sought clear, evidence-based advice about how to respond when patients ask whether vaping could help them stop smoking. Rather than promoting a single approach, the expert panel recommends patient-centred discussions that take into account individual preferences, previous quit attempts and treatment goals.

Healthcare providers are rightly encouraged to discuss the full range of evidence-based options, including nicotine replacement therapies such as patches, gum, lozenges and inhalers, prescription medications including varenicline and bupropion, behavioural counselling and, where appropriate, nicotine-containing e-cigarettes. Importantly, the guidance stresses that these recommendations apply specifically to adults who currently smoke cigarettes and are not intended to encourage nicotine use among people who have never smoked or among young people.

One of the strongest arguments supporting the recommendations comes from the expanding evidence base evaluating vaping as a smoking cessation aid. The latest Cochrane living systematic review—widely regarded as one of the highest standards in evidence-based medicine—concluded that nicotine vapes help more adults quit smoking than traditional nicotine replacement therapy while outperforming their nicotine-free counterparts. The review included dozens of randomised controlled trials involving tens of thousands of participants.

A separate Cochrane network meta-analysis comparing multiple cessation interventions also found nicotine e-cigarettes, varenicline and cytisine among the most effective treatments currently available for helping smokers achieve long-term abstinence. These findings reinforce growing international evidence that vaping can provide an effective alternative for smokers who have repeatedly failed with other cessation methods.

Why do smokers find vaping effective?

Traditional cessation medications primarily address nicotine withdrawal, while vapes also replicate many of the behavioural aspects of smoking. For long-term smokers, the familiar hand-to-mouth movement, inhalation, visible aerosol and rapid nicotine delivery help satisfy both the physical dependence and the behavioural rituals associated with cigarette use. This combination may explain why many smokers who have been unable to quit using patches or gum successfully transition away from combustible cigarettes after switching to vaping.

A central theme of the recommendations is correcting widespread misconceptions about nicotine. While nicotine is addictive, decades of research indicate that it is not the primary cause of smoking-related cancers, cardiovascular disease or chronic obstructive pulmonary disease (COPD). Those diseases arise largely from exposure to thousands of toxic chemicals produced when tobacco burns.

Understanding this distinction is essential when discussing harm reduction. Public Health England’s landmark evidence reviews, subsequently supported by the UK’s Office for Health Improvement and Disparities, have consistently concluded that regulated nicotine vaping products expose users to substantially fewer harmful chemicals than combustible cigarettes. Although researchers continue studying their long-term effects, toxicant exposure is significantly lower than with smoking.

Yet not all medical organisations share the same position. Some US health organisations continue recommending only FDA-approved cessation medications, citing concerns about the long-term effects of vaping and the presence of residual toxic compounds in aerosol.

However, the countries which have incorporated harm reduction into tobacco control policy, such as the United Kingdom, New Zealand and Sweden, have all found that lower-risk nicotine alternatives are playing an essential role in reducing smoking-related disease when used by adults who smoke.

Helping smokers make informed choices

Ultimately, the new recommendations do not position vaping as a universal solution or a replacement for established cessation therapies. Rather, they acknowledge that smokers differ, and that successful quitting often requires multiple approaches.

For clinicians, the message is straightforward: provide patients with accurate, balanced information about the benefits and risks of every evidence-based option.

For smokers, the message is even clearer. Continuing to smoke remains by far the most dangerous choice. While nicotine-containing e-cigarettes are not without risk, the evidence increasingly suggests they can help many adult smokers move away from combustible tobacco, offering an important opportunity to reduce the enormous health burden caused by cigarette smoking.

The Cost of Bad Science: How Flawed Studies And Anti-Nicotine Bias Are Shaping European Tobacco Policy

Source link

New Evidence Challenges “Mixed Research” Narrative on Vaping for Smoking Cessation

admin — Thu, 02 Apr 2026 01:37:21 +0000

Debate over vaping has been dominated, for more than a decade, by arguments that the available evidence is “uncertain” or “mixed.” That story is increasingly hard to maintain. A larger body of higher-quality research now tells a much clearer story: nicotine-packed e-cigarettes are among the most effective tools available to adult smokers trying to quit.

A significant shift is provided by a summary spearheaded by Angela Difeng Wu at the University of Oxford, which collated results from 14 systematic reviews between 2014 and 2023. By focusing on the highest-quality data, the researchers definitively sliced through years of competing interpretations. They revealed a clear trend: nicotine vaping products are more effective than any pre-existing method for cessation.

There is no shadow of a doubt: Vaping works

When lower-quality or inconsistent studies are excluded, the conclusion is remarkably consistent: nicotine vapes help more people quit smoking than nicotine replacement therapies (NRT), including patches, gums, and lozenges, as well as behavioural support alone.

This is consistent with previous work from the Cochrane Collaboration, whose living systematic review has consistently found greater quit rates among smokers using nicotine e-cigarettes compared to other cessation aids. Likewise, clinical trials published in high-impact journals such as the New England Journal of Medicine show vaping can nearly double quit success rates compared to traditional NRTs under real-world conditions.

Where vaping goes up, smoking goes down

Population-level data mirror this pattern. Cigarette smoking rates in the United States have continued to decline, according to the Centres for Disease Control and Prevention, in fact falling to all-time low levels. And this has happened in parallel to the increase in vaping, with many adults reporting that they use vaping products for cigarette cessation purposes.

This long-term drop in smoking — down from more than 40 per cent of adults in the 1960s to about 10 per cent today — is largely due to various factors, including public health campaigns. But vaping seems to be accelerating this trend among certain groups, especially among those having a tough time quitting by traditional means.

This substitution effect is critical from a harm reduction perspective. The target is not nicotine cessation at all costs but decreasing smoking-related illness by transitioning users away from combustion.

Addressing the “Evidence Gap”

The evidence supporting the role of vaping in smoking cessation is now strong, but remains woefully incomplete. The Oxford University overview introduced an “evidence and gap map” to show where more research is needed.

Importantly, we have little high-quality data from direct comparisons between e-cigarettes and newer or alternative cessation tools (e.g., cytisine, bupropion or nicotine pouches). There is also scant evidence comparing vaping with varenicline — widely regarded as one of the most effective pharmaceutical aids.

Also, most previous studies were conducted in high-income countries. That leaves open the question of how applicable the findings are to low- and middle-income settings, where smoking practices, health care systems and access to alternatives may be lacking.

Correctly interpreting uncertainties is crucial. Lack of definitive long-term data does not equate vaping with smoking. The harms of combustible tobacco are already well recognised, including links to cancer, cardiovascular disease and respiratory illness.

In fact, the main reason vaping should be considered is to reduce exposure to combustion-related toxins. This distinction is fundamental. Policies or messaging that confuse smoking and vaping jeopardise harm reduction efforts by discouraging smokers from switching to safer alternatives.

The latest science reveals a clear winner in quitting success rates

This emerging consensus around the efficacy of vaping marks a dramatic shift in the anti-tobacco landscape. There has been uncertainty shaping debates for years. Today, the balance of evidence is tipping in a similar direction. Nicotine vapes may not be a miracle solution, but for adult smokers wanting to quit, they are pretty close. They provide a potentially effective alternative, one backed by both clinical evidence and real-world results.

The challenge now is to ensure policy keeps pace with science. Harm reduction strategies can be deprived of their potential if implemented with overly restrictive measures, misinformation or by failing to differentiate products. The notion that the evidence base on vaping is ambiguous has grown stale. The best research to date invariably demonstrates that nicotine e-cigarettes are superior to many conventional cessation aids.

For the harm reduction community, one path ahead is obvious: promote access to safer alternatives, responsible use, and ensure that evidence-based public health strategies are grounded in evidence, not perception.

Understanding the Different Types of Scientific Studies on E-Cigarettes

Source link

Nicotine Science Is Changing Yet Misleading Research Risks Undermining Smoking Cessation Progress

admin — Tue, 31 Mar 2026 01:35:05 +0000

The scientific discourse about nicotine is changing quickly. Previously seen through a narrow prism of addiction, new research from a range of fields — from neuroscience to clinical medicine — is painting a much more multifaceted picture. For proponents of tobacco harm reduction (THR), this expanding body of evidence confirms a familiar maxim: it is not the nicotine per se, but rather its delivery mechanism that largely dictates harm.
Sadly, this distinction is seldom reflected in public messaging and policy frameworks. And in some instances, it is even hidden — a risk that could hinder efforts to shift smokers away from cigarettes that burn.

More flawed vape research

..if research does not clearly distinguish between product categories, it risks perpetuating the myth that all nicotine use is equally harmful.

A recent observational analysis published in The American Journal of Physiology Heart and Circulatory Physiology shows just how easily nuance can go missing. The study found a link between nicotine use and increased blood pressure levels. But many leading experts, including Nicola Lindson, Jamie Brown and Peter Hajek, were quick to point out a serious error.

The study design was flawed, and the participants had only been asked about nicotine use in the most recent five days, which meant that they hadn’t provided information about long-term smoking history. This is a major limitation, considering that dozens of vapers are former smokers, and inflation of these histories makes it more challenging to disentangle the effects of vaping itself.

For one thing, lumping together smokers and vapers into the same analytical categories threatens to distort results. The harmful effects of smoking are already well known as major cardiovascular risk factors. That means that the stronger bad effects resulting from smoking will inform these groups and outweigh the relatively weak signalling coming from vaping when they are combined. In fact, experts said the results for exclusive vapers were not statistically significant and much less pronounced than in smokers.

Public health agencies and peer-reviewed research have consistently highlighted the risk gradient between smoking and vaping. But if research does not clearly distinguish between product categories, it risks perpetuating the myth that all nicotine use is equally harmful.

Nicotine and cognitive health

In addition to risk reduction, new research is delving into nicotine’s potential effects when used under controlled conditions.
Carefully administered low doses of nicotine have been found to improve factors like working memory and mood in people with mild cognitive impairment. A more general review published in Frontiers in Ageing Neuroscience emphasises nicotine’s effects on the brain’s cholinergic system, an important system for attention and learning. This body of work suggests a dose-dependent relationship, with modest levels potentially enhancing cognitive performance. Yet, higher doses induce diminishing or negative effects.

Neuroscience discussions, including in outlets popularised by Andrew Huberman, have also explored the effects of nicotine on acetylcholine receptors and dopamine pathways, which are permissive of focus and motivation. And while researchers emphasize that nicotine should not be recreationally used for cognitive enhancement, they do highlight that the effects of nicotine are not uniform. Its impact is highly context-dependent, shaped by dose and delivery.

This expanding complexity poses a challenge for regulators.
In clinical environments, nicotine can be prescribed in specific, controllable doses. In the real world, though, that ability to regulate how much you consume is influenced by what products exist. Traditional cigarettes leave little room for control and deliver a host of harmful byproducts with nicotine.

In contrast, many reduced-risk products allow tighter control over dosage and usage behaviours. Limiting access to those alternatives may thus make it harder, not easier, for individuals seeking to align their use with safer parameters. The dissonance between our understanding of science and the constraints we face in the real world is becoming increasingly clear.

More insights from medical research

Interestingly, similar advances in other areas of biomedical research demonstrate that compounds once thought straightforward or well understood can unlock unexpected therapeutic potential. According to a recent study published in Liver Research, nicotinic acid—a variant of vitamin B3—was shown to mitigate liver damage from ischemia-reperfusion injury (IRI) markedly. This potentially life-threatening complication can occur during surgical or transplant procedures. Nicotinic acid helped protect the liver in both animal studies and human liver cells. It worked as well as, or even better than, well-known antioxidants like N-acetylcysteine.

What makes it interesting is how it works. Instead of just acting as an antioxidant, nicotinic acid directly supports the health of mitochondria—the parts of cells that produce energy. It helps remove damaged mitochondria and supports the body’s creation of new, healthy ones. As a result, researchers observed reduced inflammation, decreased cell death, and lower levels of ferroptosis, an iron-mediated form of cell injury. Liver cells also maintained better energy balance, which helped keep their normal functions.

Meanwhile, new research into the wider effects of nicotine emphasises that in both science and policy, precision matters — as does context and proportion. The story has changed around nicotine. From cardiovascular studies to neuroscience and cellular biology, discoveries are upending old assumptions and exposing a more complicated reality.

The policy disconnect that needs correcting

For policymakers, the challenge is not to discount risk but to properly recognise it—and to design systems that accurately account for relative harm. For the harm reduction community, the narrative is unchanged: access to safer alternatives in a supportive environment with straightforward messaging and evidence-based information about compliance products is a critical driver for mitigating disease burden from smoking.
Science is ever-evolving, and regulations need to keep pace.

Source link